Integration of Palliative Care in an Oncology and Hematology Unit
1 other identifier
observational
100
1 country
1
Brief Summary
The main goal of this study is to assess retrospectively the integration of Palliative Care in an oncology and hematology unit. The investigators will study the last six month of life on advanced cancer patients and retrieve data from their medical file to obtain criterias of quality of care and integration of palliative care in this population. Those criterias have been used before in other setting (Earle Criterias, ESMO Recommendations) and The investigators will compare our data to existing publications. They also hope to see if it is retrospectively possible to assess the probability of death using the Pronopall score. This will help them asses if aggressive end of life care could have been avoided using the Pronopall Score
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 23, 2019
CompletedFirst Posted
Study publicly available on registry
September 13, 2019
CompletedStudy Start
First participant enrolled
October 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2020
CompletedOctober 3, 2019
April 1, 2019
7 months
April 23, 2019
September 30, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Retrospective study of palliative care in oncohematology department
The period from January 1st, 2017 to December 31, 2018 will be examined
Eligibility Criteria
Patient who has been followed in the oncohematology Unit of the University Hospital of Strasbourg for a solid tumor or haematological cancer
You may qualify if:
- Patient aged over 18 years old
- Patient who has been followed in the oncohematology Unit of the University Hospital of Strasbourg for a solid tumor or haematological cancer
- Died within the 1rst of January 2017 and the 31st of December 2018
- The patient has not expressed an opposition to the use of his medical data during his lifetime.
You may not qualify if:
- Patient receiving allogeneic stem cell transplant
- Patient expressed during his lifetime an opposition regarding the use of his medical data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service D'Hematologie Et D'Oncologie
Strasbourg, 67091, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2019
First Posted
September 13, 2019
Study Start
October 1, 2019
Primary Completion
May 1, 2020
Study Completion
May 1, 2020
Last Updated
October 3, 2019
Record last verified: 2019-04